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ABSTRACT
Cross-validation  assesses  the  predictive  ability  of  a  model,  allowing  one  to  rank  models  accordingly.
Although the nonparametric bootstrap is almost always used to assess the variability of a parameter, it can be
used as the basis for cross-validation if one keeps track of which items were not selected in a given bootstrap
iteration.  The items which were selected constitute the training data and the omitted items constitute the testing
data.  This bootstrap cross-validation (BS-CV) allows model selection to be made on the basis of predictive
ability by comparing the median values of ensembles of summary statistics of testing data.  BS-CV is herein
demonstrated using several summary statistics, including a new one termed the simple metric for prediction
quality (SMPQ), and using the warfarin data included in the Monolix distribution with 13 pharmacokinetics
(PK) models and 12 pharmacodynamics (PD) models.  Of note the two best PK models by AIC had the worst
predictive ability, underscoring the danger of using single realizations of a random variable (such as AIC) as the
basis for model selection.  Using these data BS-CV was able to discriminate between similar indirect response
models  (inhibition of  input  versus  stimulation of  output).   This  could  be useful  in  situations  in  which the
mechanism of action is unknown (unlike warfarin).
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Introduction
Modelers may take it for granted that modeling has value, but non-modeling scientists do not always see the
value of modeling the same way modelers do.  I recall a conversation with a non-modeling faculty immunologist
who commented along these lines: “Modelers cherry pick from the vast array of known facts a subset to include
in their models, so what value do they bring? What have we learned that wasn’t already known?”  For her, most
of the value of modeling was probably educational but only in a minor way: a model could clarify current
thinking on a topic but could not offer much more.  Real discoveries were made by experimentalists like her.
In a sense, she’s right, but only if the issue of model selection is ignored, as it often is.  From where does the
value of modeling come?  This is clearly a philosophical question that may have more than one valid answer, but
I contend that most of the value of modeling arises from model selection.  (I use the phrase model selection in a
broad sense, involving discrimination of any aspect of a mathematical or statistical model.)  Picking model A
over model B,  when a priori  both seem sensible,  involves carefully weighing the merits of the models and
comparing  against  known facts.   The  process  of  model  development,  which  inherently  involves  numerous
successive instances of model selection decisions along the way, forces clarity of thought and in so doing adds
cognitive  value.   If  only one model  is  presented,  then for  all  practical  purposes  it’s  the  correct  model  by
assumption.  The deliberations involved in discriminating between models is the basis for much, if not most, of
the cognitive value of modeling.
Model selection, I believe, often seems to be under-appreciated, as if it were a mature science which scarcely
needed improvement.  The model selection literature is vastly smaller than the corpus of statistical literature not
aimed at model selection (as perusing just about any statistical journal will confirm).  It’s easier to find modeling
papers that  ignore  this issue entirely than it  is  to  find modeling papers that  provide an appendix or  online
supplementary material that goes into any depth to justify the final model chosen.  R. A. Fisher, who formalized
the notion of likelihood, considered model selection to be outside the realm of theoretical statistics—something
for the practical data analyst to take on a case by case basis [1].   Likelihood calculations presuppose some
particular model; the model is a given.
So how is model selection done?  There are at least four considerations in current practice.  The first quite
rightly involves subject matter understanding.  For example, in a pharmacometrics context a polynomial could
be used as a  basis for a  structural  model,  but  that  would have no physiological  meaning at  all,  whereas  a
compartment model using a sum of exponential terms at least has a very crude basis in physiological reality:
drugs permeate some tissues faster than others.  The second pillar of current practice involves visualization,
beginning with simple plots of one measured quantity against another and moving up to sophisticated graphical
diagnostics [2-4].  The third pillar of current practice is based on some sort of statistical hypothesis testing,
typically rooted in  P-values. The point here is that an arbitrary cutoff (such as  α = 0.05) is used to pick one
model over another.  The fourth pillar of current practice is rooted in likelihood theory and information theory:
the use of a penalized likelihood such as Akaike’s information criterion (AIC) or Schwarz’ Bayesian information
criterion (BIC) or modifications thereof [5, 6].  This is similar in spirit to the third pillar in that the choice of
model relies on a single statistic, but instead of using a cutoff the criterion is to take the model with the best
(lowest) penalized likelihood score.  There are certainly other approaches as well, such as using the minimum
description length principle as a desideratum [7] or based on the bootstrap [8], but those approaches tend to be
outside mainstream model development, at least as practiced routinely in pharmacometrics.  It behooves us to re-
examine some fundamental facts about current practice and ask if there is a discrepancy between the way things
are done and the way they ought to be done.
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Model development in pharmacometrics is an iterative process in which one starts with a simple model (after
looking at the data and verifying that they are satisfactory) and then successively considers modifications in a
stepwise process known as forward-selection, backward elimination [2, 3].  At each step of the way, whether one
is modifying the current working model by the addition of some covariate relationship or another structural term,
or whether one is considering deleting an existing part of the current working model and seeing if such a deletion
is significant, several graphical diagnostics can be used to help the decision, but often a cutoff is used based on
the change in objective function value, Δ OFV.  (The OFV is –2 × the log of the likelihood; the actual calculation
of an approximation to the likelihood depends on algorithmic choices that involve a tradeoff between accuracy
and calculation time.  Since the likelihood is a product of probabilities (p. 104 of [9]), each of which is between
0 and 1, the log likelihood is negative, and so the OFV is a positive number where the smaller it is, the better the
fit.)  If the addition of a parameter results in a Δ|OFV| ≤ cutoff, then this parameter is considered insignificant
and would not be included on purely statistical grounds (although perhaps the modeler has other reasons for
wanting it to be included anyway), and conversely, a Δ|OFV| > cutoff would result in the model addition being
retained.  If one formally compares nested models using a likelihood ratio test, the Δ OFV is approximately
distributed according to a Χ2 distribution for a pre-specified α value and number of degrees of freedom equal to
the number of additional parameters estimated in the larger model.  For such a distribution with one degree of
freedom a difference more than cutoff = 3.84 is significant at the conventional α = 0.05 level used in hypothesis
testing [2].  For backward elimination a more stringent α level is often used, e.g. α = 0.001.  If the models are not
nested, then a likelihood ratio test cannot be done, but nevertheless the same cutoff value can still be used as a
criterion for retaining the model modification or not.
Several features of this forward addition, backward elimination paradigm should be noted.  First, it is by far
the dominant paradigm for model selection in pharmacometrics.  Second, it is time-consuming.  The number of
potential models grows combinatorially with the number of model components.  With tight deadlines, a modeler
might of necessity skip the evaluation of some models that he’d rather look at and settle for what he hopes is
good enough.   This  disadvantage  can  be  offset  by  the  third  point:  since  it  is  essentially  algorithmic,  it  is
amenable to automation.  For example, Marc Lavielle developed an automated model building platform for
Rsmlx [10].  Fourth, the forward addition, backward elimination modeling approach winds through the sample
space, eventually settling on some model as best,  but if a different trajectory in the sample space had been
followed, perhaps if covariate B had been evaluated prior to covariate A, then a different final model may have
been selected.  This is an example of what Leo Brieman called the  “Rashomon effect”  [11]:  in complicated
multivariate data sets, the same data can often be explained almost as well by a large number of very different
models.  It may be in vain to try to find a global optimum when there are many predictors, as the differences in
objective function value may be insignificant.  While the forward addition, backward elimination procedure may
fail to give the best model for a given data set, fortunately the best model it does find might not be too bad.  A
few other fundamental facts pertinent to this procedure are worth strongly emphasizing (in order of increasing
concern):
1. The justification of the cutoff is based on P-values that are only approximately valid.
2. Each model choice is based on a single realization of a random variable.
3. It aims to improve fit, not prediction.
Each of these points will be more fully discussed further below.
The  justification  of  the  cutoff  is  based  on  P-values  that  pertain  to  a  distribution  that  is  only
approximately valid.  The basis for favoring one model over another—the Δ OFV—is only asymptotically Χ2
distributed, which implies that P-values for the Χ2 distribution are only approximately valid; they are not exactly
valid for the real situation at hand, so the statistical justification of changes to the working model actually being
made with a (1 – α)% probability is incorrect.  This weakens the justification for using a particular Δ OFV as a
cutoff for accepting a model change (such as 3.84 for the addition of a single parameter at α = 0.05).  It might be
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true that  Δ OFV sufficiently lies close to a Χ2 distribution [12], but there is no guarantee.  The quality of the
approximations depends in part on the accuracy used for the likelihood calculation (and in part on the fact that
sampling distributions of random variables are relevant here, discussed next).  Better results are obtained using
more accurate likelihood approximations [2, 13-15].
At  each  decision  point  in  the  model  development  process,  the  model  choice  depends  on  a  single
realization of a random variable.  That the  P-values pertain to a distribution that’s only approximate is one
issue, but the fact that they are used at all to provide model justification is another issue.  P-values have long
been controversial, as evidenced by the many authors and papers who have criticized P-values for decades.  For
a good place to start, see the ASA’s statement on  P-values and the papers and reviews therein  [16].  Most of
these deal with the fact that P-values are easily and often misunderstood, but misunderstanding is a problem of
statistical education, not the statistics themselves.   Although it is not widely appreciated,  P-values are random
variables with their own probability distributions—just like the sample mean or the range.  (Here for clarity I
follow the statistical convention of using a capital letter to denote a random variable  X and some particular
realization of it by a lower case letter, x.  Hence P-values emphasizes the fact that these quantities are random
variables pertinent to some probability function, stopping rule, and sample space, and  p-values emphasizes a
particular realization based on a particular data set.  Unfortunately statisticians rarely follow this convention for
P-values.)  When a particular  p-value is obtained in order to make an inference, that p-value is almost always
obtained using the full,  actual  data set.   Some statistics,  like  the median,  are robust  to  sampling variation,
whereas other statistics, like the range, are not at all robust.  As a basis for making inferences intended to be
reflective of an unobserved, underlying population from which the observed sample is merely an instantiation, it
would be very desirable if P-values were robust to sampling variation.  How robust are they?  Despite being a
mainstay of routine statistical inference for decades, this question was largely ignored.  It was finally addressed
in 2011 by Dennis Boos and Leonard Stefanski [17] who noted:
Good statistical practice demands reporting some measure of variability or reliability for important
statistical estimates. For example, if  a population mean  μ is estimated by a sample mean  Y̅ using an
independent and identically distributed (iid) sample Y1, . . . ,Yn, common practice is to report a standard
error s/√n or a confidence interval for μ, or their Bayesian equivalents. However, the variability of a p-
value is typically not assessed or reported in routine data analysis, even when it is the primary statistical
estimate.
More generally, statisticians are quick to emphasize that statistics have sampling distributions and that
it is important to interpret those statistics in view of their sampling variation. However, the caveat about
interpretation is often overlooked when the statistic is a p-value. With any statistic, ignoring variability
can have undesirable consequences. In the case of the p-value, the main problem is that too much stock
may be placed in a finding that is deemed statistically significant by a p-value < 0.05. In this article we
systematically  study  p-value  variability  with  an  eye  toward  developing  a  better  appreciation  of  its
magnitude and potential impacts, especially those related to the profusion of scientific results that fail to
reproduce upon replication.
Their paper is certainly worth reading, but the short answer is that  P-values have lots of variability and are
basically only valid to an order of magnitude.  It is pointless to get excited if p = 0.04 and disappointed if p =
0.06 for a conventional α = 0.05.  As Boos and Stefanski showed, if you tweak the data slightly, for example by
the bootstrap, you’ll get a different p-value—possibly very different.  In my view, this fact is very damning for
the use of individual p-values as a primary inferential tool.
Although P-values and hypothesis testing are by far the most common model selection tools in science as a
whole, in pharmacometrics model development one looks at the Δ OFV or a penalized likelihood such as AIC
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rather  than  actually  at  a  p-value.   As  with  P-values,  the  log-likelihood  (and  hence  OFV)  and  penalized
likelihoods  are  random  variables  with  their  sampling  distributions,  depending  only  on  the  model  and  the
particular realization of data obtained in nature from some unknown distribution.  The difference between two
OFVs is also a random variable because the two OFVs depend on different models but the same data.  Boos’ and
Stefanski’s paper investigated the robustness of  P-values, not AIC or BIC scores; however, AIC and P-values
(based on the F-test) are related for nested models so that if you know one, you can get the other (p. 27 in [3]).
Hence it would not be surprising to find that AIC and the like are also not very robust.  The Results section of the
present work bears out this hunch.  Put simply, it can be dangerous to put much faith in a single AIC value or Δ
OFV.
The forward addition, backward elimination procedure aims to improve a model’s fit to current data,
not its predictive ability.  After the initial graphical exploration of the available data, all subsequent stages of
the forward addition, backward elimination paradigm are aimed at improving the fit between the working model
and the observed data.  In discussing the model development process, the NONMEM V manual [18] states, “A
more complex model is acceptable only if the complexity can be justified by some significant improvement in
the  fit.  To  evaluate  whether  this  has  been  accomplished,  several  measures  should  be  examined;  no  single
measure suffices.”  The implicit assumption is this:  the better the fit, the better the model.  This assumption
should  be  re-considered,  since  not  surprisingly  working  toward  improving  the  fit  can  lead  to  overfitting.
Overfitting is undesirable because then one is fitting not only the signal (the basic patterns in the data) but also
the random noise, and as a result the predictive ability of the model worsens.  The usefulness of a model depends
on its intended purpose, but generally speaking a model that makes good predictions of future data will be far
more useful than a model that merely fits observed data well.
It is with these shortcomings of the current forward-addition, backward elimination paradigm in mind that the
present work was undertaken.
Theoretical
Bootstrap cross-validation
In Bayesian inference one updates one’s prior beliefs with observed data according to Bayes’ rule.  Basing
inferences on data that were actually obtained is obviously appealing, but it comes at the cost of requiring a
prior, which, rightly or wrongly, has been controversial.  In contrast, frequentist inference is based on sampling
distributions.  In other words, frequentist inferences depend not on only what was observed but also on data sets
that could have been observed but weren’t [19].  In this sense resampling approaches such as the bootstrap and
cross-validation are purely frequentist: they generate many sets of “fake data” that are not identical to the actual
observed data set but which are derived from the observed data and hence are very plausible.
Nonparametric bootstrapping is resampling with replacement so that from a single, original sample, one gets
a set of bootstrap samples; their distribution mimics the unobserved, underlying distribution from which the
original sample was drawn.  The emphasis is almost always to get an estimate of the variation of some statistic
of interest, often one that would be difficult to do from purely theoretical grounds.  For hierarchical or mixed
effects models, as population PK and PD models typically are, the resampling should be at the level of the
individual.  In cross-validation the data are segregated into mutually exclusive subsets, one for “training”, i.e. for
ordinary parameter estimation as one would do with the entire data set, and the rest of the data is used for testing
the results from the training set.  The goal is to estimate how well a model fits data that were not used to develop
the model, i.e. get an assessment of prediction error.  While external validation using an independent data set is
most persuasive for predictions,  cross-validation is the next best  thing to more real  data,  which are usually
financially or otherwise impractical to obtain.
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Although the emphasis in the bootstrap is typically parameter estimation and related confidence intervals, one
can also use it as a basis for cross-validation.  To do so one needs to keep track of not only which items were
selected  by  the bootstrap’s  sampling with  replacement,  but  also  which  items were  not  so selected.   These
constitute the training and testing data sets respectively.  The probability that any one item will be selected by the
bth bootstrap sampling procedure is P (observation i ∈ bootstrap sample b) = 1 – (1 – 1/N)N = 1 – e–1 ≈ 0.63212
(as N → ∞), and hence this is known as the 0.632 bootstrap [19, 20].  However, I shall refer to it as bootstrap
cross-validation (BS-CV), which I think is more descriptive.  The probability of not being selected is 1 – (1 – e –1)
≈ 0.36788.  Roughly 2/3 of the items will be selected (training set) and 1/3 will be in the testing set.  In this sense
the bootstrap is a bargain: you get cross-validation almost for free. (That said, the R code for doing a bootstrap
(sampling with replacement) is just 1 line, but actually implementing this for mixed effects models is much more
involved.  The R functions are included in the supplemental Appendix.)
The bootstrap cross-validation work flow goes like this: data → training and testing subsamples → do some
statistical procedure(s) → summary stats on both training and testing data → repeat → get ensemble of testing
and training errors → report such errors.  From a frequentist perspective this is a much better measure of a
model’s true accuracy than drawing all  inferences of accuracy assessment from only 1 sample.   For model
selection, pick the model with smaller testing errors (and hopefully smaller variance).  The notion “the better the
model fits the data, the better the model” is naive because it ignores the problem of over-fitting.  However, for
the testing data used to evaluate predictive ability, it is true: the better the fit, the better the prediction, and hence
the better the model.
Summary statistics for use with BS-CV
The fundamental hypothesis of this research is this: Can the 0.632 bootstrap be applied to nonlinear mixed
effects models such as those arising in population PK and PD so as to provide a useful tool for model selection?
The short answer is yes, as shown in the Results, but to do so requires some summary sample statistic to serve as
a common basis for comparison across models.  Many summary statistics are possible, and I wanted to cast a
reasonably wide net.  Hence a secondary question is this:  Which of the following summary statistics is most
useful for model selection?:  –2LL, AIC, BIC, RSS, RMSE, SAD, MAD, SMPQ, ε-shrinkage.  These are defined
below:
 –2LL is –2 × log(likelihood), the likelihood being the primary probabilistic measure of fit. Same as OFV.
 AIC ≡ –2LL + 2p is Akaike’s information criterion.  Here p is the number of parameters.
 BIC ≡ –2LL + log(N) p is Schwarz’ information criterion, a.k.a. Bayesian information criterion.
 RSS ≡ Σ (Yi – Ŷ)2 is the residual sum of squares.
 RMSE ≡ √[(1/n)Σ (Yi – Ŷ)2] is the root mean squared error.
 SAD ≡ Σ |Yi – Ŷ| is the sum of absolute deviations.
 MAD is the median absolute deviation.
 SMPQ ≡ –log(1 – r2) is the simple metric for prediction quality.  Here the sample correlation coefficient
r pertains to the zero-intercept goodness of fit line of individual predictions versus observations.
 ε-Shrinkage ≡ 1 – SD(IWRES) where SD(.) denotes standard deviation and IWRES are the individual
weighted residuals [21].
The above summary measures include both probabilistic (–2LL, AIC, BIC) and non-probabilistic,  purely
geometric measures of fit that depend only on the residuals: RSS, RMSE, SAD, MAD, SMPQ.  The ε-shrinkage
is somewhat in between, in that strictly it depends only on the residuals, but one would not normally calculate
IWRES in the absence of a probabilistic context.  The weighting factor by which the residuals are weighted in
IWRES does not depend on the residuals.
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RSS and RMSE depend on squared error, as is common throughout statistics, so extreme values will count
more.  In the analogous quantities SAD and MAD all errors count the same, i.e. linearly with magnitude.  It is
not easy to see which would be more useful for model selection a priori.
The usual Pearson correlation coefficient r is a measure of linear association between two random variables
and not a measure of fit (p. 18 in [3]).  However, here the line of interest is the goodness of fit line of identity of
observations versus  predictions,  so the particular  r2 here  is in fact  an excellent  measure  of fit.   It  is  more
convenient to modify it as seen here, since –log(1 – r2) → ∞ as Δ(observed, predicted) → 0.  Hence this statistic
is  indeed  a  simple  metric  of  prediction  quality,  easily  obtained  from  summary  statistical  output  of  many
statistical  programs.   The predicted values refer  to  individual  predictions  (IPRED in NONMEM jargon)  as
opposed to population predictions (PRED in NONMEM).  The term “simple” in “simple metric for prediction
quality” is meant to imply that other similar quantities could also be made.  None of them are as intuitively
desirable in my opinion as the SMPQ, although this could be explored in future work.
As  data  become  sparse  empirical  Bayes  estimates  (EBEs)  approach  their  population  distribution  (“η-
shrinkage”) [22], and also the distribution of individual weighted residuals (IWRES) shrinks towards 0 (“ε-
shrinkage”) [21].  This is therefore a measure of under- versus over-fitting.  NONMEM calculates ε-shrinkage,
but  Monolix  does  not.   However,  Monolix  does  provide  two  estimates  that  one  could  use  to  calculate  ε-
shrinkage, one being from EBEs and the other from simulations.  Both of these variations were used herein.
Methods
For pharmacometric software to execute BS-CV it is necessary to be able to get likelihood values (or at the
very least residuals) without doing any optimization; this is for the testing data.  If one uses NONMEM one can
use the MAXEVAL=0 option on the estimation step.  Monolix (used herein) uses the SAEM algorithm so that in
principle the estimation task is needed.  However, it is possible to fix parameters to set the number of iterations
to 1 and then use the R API function getEstimatedLogLikelihood() with either the default importance
sampling (more accurate) or the linearization approximation (faster).  Details are described further on the Lixoft
website [23]  and in Chapter 9 of [9].
To execute BS-CV, B = 100 bootstrap iterations were generated according to code in the Appendix from the
warfarin data [24] supplied with Monolix.  These data describe the results of a single oral dose of warfarin (1.5
mg/kg body weight) to 32 subjects (27 males, 5 females) at t = 0.  Some subjects’ first measurement was at 24 h,
too late for good information on the absorption phase.  The PK variable (y1) is concentration and the PD (y2) is
effect (anti-coagulant; prothrombin complex response).  Age, weight, sex were covariates in the data set, but
since there were so few females, sex was set to IGNORE in Monolix.  These BS data were saved to disk.  The
same data were used for all models, hence making a fair comparison across models.  A series of PK and PD
models was generated using Monolix 2018R2 [25], and then an R script incorporating the Monolix R API was
used to get  quantities of  interest  and save them to a data  frame.  This data  frame was then used to  make
appropriate graphs using the R package ggplot2 [26].  Computational details are in the supplemental Appendix.
Pharmacokinetic Modeling
The 13 pharmacokinetic models tested are summarized in Table 1.  Following Monolix’ terminology, the
Observation Model refers to the error model, and the Individual Model column shows the form which the inter-
individual variability takes for each parameter, including covariates if any.  Models 1-6 are all 1-compartment
models.  Model 1 is just the basic 1-compartment model with no covariates.  All the other models have a lag time
(tlag parameter).  Models 7-13 are 2-compartment.  The structural models are as follows [27] (where C(t) = 0 for t
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< tlag, D is dose, and bioavailability is assumed 1): C (t )=
Dka
V d (k a−ke)
(e−k e (t −t lag)−e− ka(t −tlag)) for models 1-6 (but
tlag = 0 for model 1) and C (t )=D (Ae−α (t −tlag )+Be− β (t −t lag)− (A+B )e−k a (t − tlag)) where
α=
Q
V 2
Cl
V 1
β
β=1
2( QV 1+ QV 2+ClV 1−√( QV 1+ QV 2 +ClV 1)2−4 QV 2 ClV 1)
A=
ka
V 1
Q
V 2
−α
(ka−α ) (β−α )
B=
ka
V 1
Q
V 2
−β
(ka−β )(α− β)
The parameters Cl, V1, V2, Vd, and Q have their usual PK meanings.
An earlier model selection project executed using NONMEM, which allows for more flexible error modeling
than does Monolix, showed that manipulating the error model gave a considerably better fit at the cost of only
one additional parameter.  This was the motivation for using 3 error parameters for models 7 and 8, whereas all
the other models have 2. 
Pharmacodynamic Modeling
Pharmacokinetic model 9 was deemed to be the best of the PK models considered (as discussed later), and
was therefore used with all individual PK parameters held fixed for all the pharmacodynamic models tested.
Besides providing another example of the utility of BS-CV, an additional goal for PD modeling was to see if one
could  distinguish  between  indirect  response  model  (IRM)  type  1  (inhibition  of  input)  from  IRM  type  4
(stimulation of output) based purely on statistical grounds.  This could be useful in cases where the mechanism
of  action  is  unknown,  unlike  warfarin.   These  two  models  have  the  same  general  shape  but  very  subtle
differences.   I  investigated  12  PD models  in  4  patterns  of  3  each:  first  the  basic  model,  then  with a  Hill
parameter, then with the most suitable covariates identified by a plot of parameter correlations versus covariates
(using the Hill parameters).  Models 1-3 are variations on IRM-1; models 4-6 are variations on IRM-4; models
7-9 are also variations on IRM-1 but with Imax = 1 (fixed); and models 10-12 are combined IRM-1 and IRM-4:
they have both inhibition of input and stimulation of output.  With the covariates used, the list of PD models is as
follows:
Model 1: IRM 1 (inhibition of input); 4 parameters: R0, kout, Imax, IC50
Model 2: Ibid + Hill parameter (= “gamma”)
Model 3: Ibid + covariates: Hill(LnWt70), IC50(LnAge30), kout(LnWt70)
Model 4: IRM 4 (stimulation of output); 4 parameters: R0, kout, Emax, EC50
Model 5: IRM 4 with Hill parameter
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Model 6: Ibid + covariates: Emax(LnWt70) and EC50(LnAge30)
Model 7: IRM 1 with Imax := 1.  3 parameters: R0, kout, IC50
Model 8: Ibid + Hill parameter
Model 9: Ibid + covariates: IC50(LnAge30), Hill(LnWt70)
Model 10: IRM 1 combined with IRM 4.  6 parameters: R0, kout, Imax, IC50, Emax, EC50
Model 11: Ibid but with 2 Hill parameters
Model 12: Ibid + covariates: IC50(LnAge30), kout(LnAge30), Hill1(LnWt70)
The error models all used the additive + proportional error model (i.e. combined1 in Monolix’ terminology).
Similarly to the PK models, all the parameter distributions of the structural models were lognormally distributed.
Just to be clear on notation, “Hill(LnWt70)” means that the individual Hill parameter is adjusted by weight, log-
normally scaled by the mean weight (70 kg): log(Hi) = log(Hpop) + βH log(wti/70) + ηH,i and similarly for the other
covariate relationships.
Results
PK results
The top, middle, and bottom panels of Figures 1-10 show the various summary statistics of interest described
above for models 1-13 for the original data, the bootstrap training data, and the testing data respectively.  For
most of the figures the three panels are on the same scale.  Note that for the statistics –2LL, AIC, BIC, RSS, and
SAD, the median values for the training data are generally very different from the medians for the testing data,
reflecting the fact that in the testing data set there is simply less data (due to smaller sample sizes) and less
information.  In contrast the statistics RMSE, MAD, SMPQ and ε-shrinkage are not so sensitive to the sample
size and information content.
The likelihood based figures (Figures 1-3) are all very similar.  These summary statistics for the original data
are slightly higher than the medians of the corresponding statistics of the training data, suggesting that there may
be slightly more information in the original data than in a typical bootstrap sample.  As one would expect, Figure
1 shows a steep drop in –2LL (better fit) when going from model 1 to model 2, i.e. the inclusion of a lag time for
absorption.  The addition of covariates further improves the fit, but less so, and the same is true for going from a
1-compartment model to a 2-compartment model.   Figures 2 and 3 show the analogous AIC and BIC plots
respectively.  There is nothing unusual in either the –2LL, AIC, or BIC plots with respect to the original or the
training data for any of the models.  Based on the traditional criterion of choosing the model with the lowest
AIC, the best model would be model 8 (AIC = 660.5397), followed closely by model 7 (AIC = 660.7185).
Recall that these two models have three error parameters,  whereas all the others have two.  In contrast,  the
testing data show a much worse fit  (higher  –2LL, AIC, and BIC) for models 7 and 8 than for the other 2-
compartment models (going by medians for each model).  Model 7 is even worse than the basic, no-frills model
1.  Model 5 is the best (slightly) among the 1-compartment models, and the other 2-compartment models are all
about the same.
Figure 4 shows that the residual sums of squares for the original data are all similar regardless of model, and
in fact models 7 and 8 have among the highest RSS.  However, in the training data models 7 and 8 show
dramatically lower RSS, indicating a much better fit.  This is overfitting as seen very clearly in the testing data:
models 7 and 8 have by far the worst predicted fits.  Model 7 is worse than model 8.  Figure 5 tells the same
story for the RMSE, which is to be expected given the similar nature of the statistics.
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Figures 6 (SAD) and 7 (MAD) are also similar to Figures 4 and 5.  It is a bit easier to discriminate among the
other models using Figure 6 than 4 since the former does not change the ordinate scale as drastically, dealing
with the magnitudes of the residuals rather than the magnitudes of the squares of the residuals.  Models 7 and 8
are shown to be by far the worst with these statistics (highest predicted errors), but surprisingly model 1 was the
best among the 1-compartment models, as judged by SAD for both the training and the testing data sets, and also
by the original data.  This contrast between the likelihood (–2LL, AIC, BIC) and the pure residual (SAD, MAD)
results (apart from models 7 and 8) is a bit surprising and difficult to explain.  The other 2-compartment models
are all very similar.  The results for MAD (Figure 7) are very similar to those of SAD (Figure 6).
Figure 8 shows SMPQ, which is arguably the best statistic in the set of statistics considered on a priori
grounds.  It is a direct measure of how well a model’s predictions fit the observations.  The original data and the
training data show that the basic model, model 1, has the worst fit, models 2-5 are much better and are all about
the same, and the 2-compartment models are better still and also all about the same.  With so few covariates this
warfarin data set is a very simple, so it is not surprising that models differing only by the arrangement of two
error parameters (combined1 versus combined2) behave so similarly.  The testing data are similar except for
models 7 and 8, which show a remarkably worse fit.  Model 9 has the highest median score (barely) for the
testing data, and therefore that was the model that was used going forward with the PD modeling.
Figures 9 and 10 show ε-shrinkage calculated using either the EBEs or simulated data.  Unlike with most of
these plots, the scales for the original data were left to their default settings to highlight the differences, but they
are similar to the medians for the training data.  The training data ε-shrinkage using the EBE-derived values are
small but positive (Fig. 9), whereas the values using simulated data are very close to 0 except for models 7 and 8
(Fig. 10).  The testing data in Fig. 9 had medians all near 0 (some above, some below), except for models 7 and
8, while the testing data in Fig. 10 were all negative.  In both figures the training data show strongly positive ε-
shrinkage for models 7 and 8, but the testing data show strongly negative ε-shrinkage for these same models.  It
is not obvious why this should be so.  The medians for all the testing data are negative for ε-shrinkage via
simulation.  The ε-shrinkage values are intriguing but only significant for models 7 and 8, which have different
signs between the training and testing data.   The ε-shrinkage by simulation (sampling from the conditional
distribution) ought to be more accurate than by EBEs for the same reasons that sampling from the conditional
distribution is preferred in Monolix, as a way to mitigate the effects of shrinkage [28] .
PD results
As to whether one can distinguish between IRM-1 and IRM-4 based on purely statistical grounds, the short
answer is yes.  Model 1 has a much better fit based on likelihood measures than does model 4, but not based on
other measures such as RSS or SAD.  In this sense the PD data do not tell as clean a story as do the PK data.  If
one includes additional parameters such as the Hill parameter and covariates, even this distinction is eroded.
For the warfarin PD data used, indirect response model 4 (stimulation of output) by itself, with no additional
parameters, was noticeably worse than the other models, such as IRM-1 (inhibition of input) as seen by –2LL,
AIC, and BIC even using the original data.  Figures 11 (–2LL), 12 (AIC), and 13 (BIC) are all very similar to
each other and showed similar patterns for training and for testing data.  A large improvement to fit was seen for
IRM-4 when adding a Hill parameter (model 5 compared to model 4), but small improvements to fit were seen
as one added parameters to the other models.
Unlike the likelihood metrics, the testing data panels in Figures 14 (RSS) and 15 (RMSE) show evidence of
overfitting in going from model 2 to model 3 and again from model 11 to model 12.  These changes involve the
addition of covariates to the previous model.  Models 1, 2, and 6 are the best by RMSE.
Figures 16 (SAD) and 17 (MAD) tell the same story as do Figures 14 and 15, but the differences are less
pronounced for SAD than for RSS.  At least for these data and models, MAD seems to be more useful than SAD.
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Clearly the addition of covariates does not help the predictive power for the PD models considered for this data
set based on these metrics.  (Compare models 2 and 3; 5 and 6; 8 and 9; and 11 and 12.)
Figure 18 (SMPQ, i.e. –log(1 – r2)) confirms that the addition of covariates isn’t helping, except when going
from model 5 to model 6 and maybe from model 8 to model 9.  If one were to focus only on improved fit, one
would not pick model 1, but model 1 has the highest median SMPQ score for testing data among the candidate
models and hence the best predictive ability (however, the values for all PD models are extremely similar as
shown Table 2).  These data are another example of how pursuing the best fit with a model, such as in the usual
stepwise regression approach used ubiquitously in pharmacometrics, would lead to a model that is not the best in
predictive ability.
Figure 19 shows  ε-shrinkage based on EBEs,  and those medians are all  positive.   Figure 20 shows the
analogous ε-shrinkage based on simulations, and those medians are all negative.  The significance of the sign is
unclear to me at this time.  The relative values of the medians across models in both graphs is suggestive of the
same patterns seen in the other graphs.
Individual plots are contained in the Supplemental Information.
Discussion
With respect to coaxing meaning out of data, the question, “What do I find persuasive?” involves both one’s
modeling philosophy and human psychology.  The philosophical foundations of statistics lurk just beneath the
surface  and  inform  and  guide  the  actual  calculations  (Bayesian,  frequentist,  and  so  on).   Psychological
considerations such as familiarity, consistency with prevailing theories, whether one follows historical norms,
rhetorical ability, and the reputation of the analyst are also important—especially with regards to persuading
others.  Often modelers focus their efforts on developing models which fit the available data very well.  This is
the guiding philosophy underlying the forward selection, backward elimination approach that is ubiquitious in
pharmacometrics.  The problem with “the better the fit, the better the model” is that working to improve the fit
can lead to over-fitting.  A better guiding philosophy would be to focus on making models which have good
predictive ability and are parsimonious in their explanatory ability.
The most persuasive, highest impact models make surprising predictions that are externally validated in
subsequent experiments, such as the Standard Model in particle physics.  However, requiring additional data sets
from subsequent experiments is a very high bar to persuasion and has its own set of problems, such as cost, time,
differences in experimental setup, and the subtle differences in skills of the people running the experiments.
Cross-validation  offers  a  computationally  demanding  but  otherwise  cost  effective  approach  for  internal
validation, allowing models to be compared on an even footing based on their predictive ability.
There are multiple forms of cross-validation.  At one extreme would be 2-fold cross-validation, where half of
the data are reserved for testing and half for training.  Since only half of the data (one could use even less with
large data sets) are used for model generation (training), models which really need to have lots of data to support
them would be biased against; thus 2-fold CV favors simpler models.  At the other extreme would be leave-one-
out cross-validation (LOOCV) where only a single datum is omitted from the training set.  LOOCV is nearly
unbiased but has high variance [20].  Bootstrap cross-validation lies in between these extremes.  It has an overall
good balance between bias and variance [20, 29].  Although BS-CV has greater bias than LOOCV, it has lower
variance and better performance and tighter confidence intervals [30].  Adjustments can be made to lower the
bias [31], but they would complicate the discussion and are unnecessary for model selection.  By keeping track
of which items are not selected in any given bootstrap iteration, this research illustrated the utility of BS-CV as a
practical means of model selection in pharmacometrics.  Future work should include efforts to quantify the bias,
variance trade-off using simulated data sets of varying sizes [12], varying types and numbers of covariates,
different dependent variables (continuous, time to event, and so on), and various cross-validation approaches.
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As shown in [29] the bias of BS-CV (0.632 bootstrap) can vary significantly depending on the data set, so it is
important to use realistic PK or PD data sets to get a richer set of experience in the pharmacometrics context.
Simulated data allow one to make an assessment of bias.  However, when using simulated data one should
remember that although there is a true generative model, for a data set of finite size the best model may not
necessarily be the model used for the simulations; one can generate data sets that are better explained by simpler
models.  This hearkens back to the question of what is persuasive, and in part for this reason a real data set was
used for this study.
Besides multiple forms of CV, there are also multiple possible summary statistics one could use as the basis
for comparison across models.  In this study several probabilistic statistics (likelihood based) and several non-
probabilistic  statistics  (based  only  on  residuals)  were  examined.   When  used  with  testing  data  the  SMPQ
provides an especially simple and versatile assessment of predictive ability.  One should distinguish between the
summary statistics used to provide a basis for a “common currency” across models (i.e., –2LL, AIC, BIC, RSS,
RMSE, SAD, MAD, SMPQ, and ε-shrinkage) from the summary statistic actually used to compare them, in this
case the median.  Other measures of overlap between clouds of points pertaining to BS data of various models
could be used, for the purpose of model selection such complications seem unnecessary.  Comparing  medians for
predictive accuracy by BS-CV seems adequate.
Resampling as by BS-CV greatly adds to the time taken for modeling.  Does one always need to do some
form of cross-validation such as BS-CV?  No, only when it’s important to have good predictive models (but if
it’s not important,  why is the modeling done?).  If the final model will  be used as the basis for simulating
expensive clinical trials or if important clinical or financial decisions depend on the model, then  it absolutely
makes sense to get the model selection right and to have as high a confidence in the chosen model as possible.  If
one were completely confident that one was erring on the side of under-fitting and not over-fitting, then there
would be no need to do CV of any sort.  This may be true at the beginning of a modeling endeavor, using simple
compartmental  models  and  before  lots  of  covariates  are  included  with  possibly  different  functional  forms.
However, as candidate models become more complicated, the risk of over-fitting grows, and hence the need to
evaluate  predictive  performance  and  not  merely  fit.   To  balance  the  desideratum of  finishing  a  modeling
endeavor in a timely manner with the desideratum of having models with good predictive performance, my
recommendation would be to do BS-CV either on only the top 10-20 final candidate models or to do BS-CV on
the  top  5  or  so  candidate  models  as  one  proceeds  along  with  either  manual  forward  selection,  backward
elimination or an automated equivalent and to re-do BS-CV from time to time as new models are generated.  In
order to have a benchmark for models known not to suffer from over-fitting, I suggest including the simplest
model examined (such as a simple 1-compartment model with no covariates in the present case) in at least the
first round of BS-CV.
 An obvious question is how many iterations of BS-CV should be done.  To get a very good estimate of the
covariance between some random variables, it may be necessary to do very many (> 1000) iterations.  However,
the issue here is model selection, not getting very tight confidence intervals for some parameter.  For BS-CV it is
only  necessary  to  do  enough  bootstrapping  that  one  can  have  good confidence  in  comparing  the  medians
(assuming that the median is the basis for comparison).  In the present study 100 BS iterations were done, which
should be plenty to have enough confidence in the medians to make a comparison.  Note that these bootstrapped
data sets were saved to disk prior to doing any modeling on them in order to be sure to have a fair comparison
from one  model  to  another  without  the  complication  of  comparing  different  models  with  different  sets  of
bootstrapped data.  If that were not the case, more iterations would be needed, but how many more is unclear.
The phrase “to have confidence in the medians” may suggest that standard errors of the medians need to be
calculated so that formal statistical tests could be done, instead of merely comparing medians directly.  If one
really wanted to, one could do a bootstrap of the bootstrapped summary statistics and thereby get confidence
intervals for the median values for the statistics of interest and even do permutation tests to put a p-value on the
difference between the medians of two models.  (In the spirit of cautioning against drawing inferences using
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single instances of random variables, I would suggest using a distribution of p-values—if that’s what one finds
persuasive—rather than single instances.)  However, if one is tempted to look for p-values or for the overlap of
confidence intervals for BS-CV summary statistics between models, one really needs to remember that statistics
is quantitative epistemology and to think carefully about the philosophical underpinnings and ask, “What exactly
am I trying to accomplish?”  In hypothesis testing one has a model to be nullified with data—the null model.  A
situation in which one might want to do formal nonparametric hypothesis testing between the distributions of
bootstrapped summary statistics would be if you’re designing a clinical trial  and model A will  cost  you $x
whereas model B will cost you more.  Now you do have a reason to prefer model A, and you would want to
know if model B really is that much better as to justify model B, so it would make sense to ask (for a one-sided
test), “Is model B significantly better than model A?”  Using model A as the null hypothesis would be sensible in
such a case: if you fail to reject model A as inadequate, then stick with it.  However, if the goal is just to pick a
model with good predictive ability and there is no a priori bias for or against any one model, then I see no point
in trying to put a p-value on the summary data just to be able to say, “Models A, B, and so on are significantly
different from each other (a phrase which the American Statistical Association finally officially deprecates [32,
33]) according to a traditional hypothesis test, which ignores P-value variability anyway [17, 34].”  For the task
of picking a single model to use for downstream purposes such as clinical trial simulations, comparing medians
directly is adequate.
Forward addition, backward elimination is an algorithmic paradigm which yields models that are probably
by and large good models (due to the Rashomon effect) but which nevertheless has a shaky epistemological
foundation.  The results of BS-CV may or may not agree with model selection based on traditional criteria such
as AIC.  In the present case PK models 7 and 8 (with 3 error parameters, versus 2 for all others) were the best by
AIC on the original data but were by far the worst models when seen in the light of BS-CV.  By comparing the
testing data to the training data across the various summary statistics, a consistent picture emerges in which these
models are seen to be highly overfit.  Apparently an additional parameter in the error model gives one a greater
ability to fit (and over-fit) data than does an additional parameter elsewhere.  This example should serve as a
warning against using AIC or BIC on the original data as the basis for model selection.  For the warfarin PD data
used, indirect response model 4 (IRM-4, stimulation of output) by itself, with no additional parameters, was
noticeably worse than the other models, such as IRM-1 (inhibition of input) as seen by both AIC using the
original data and also by BS-CV testing and training data.  A large improvement to fit was seen for IRM-4 when
adding a Hill parameter, but small improvements to fit were seen as one added parameters to the other models.
The model with the highest SMPQ score was model 1, which also happens to be the accepted model for warfarin
based on its mechanism of action [35].  By looking at medians of distributions of random variables instead of
single  instances,  BS-CV  gives  greater  assurance  in  the  results.   BS-CV  is  thus  seen  to  be  useful  for
discriminating between IRM-1 and IRM-4.  However, the generality of this should be studied further in other
drugs and data sets.
The use of random variables such as P-values, AIC, and BIC based only on the original data and a model of
interest has been the standard way of frequentist  model development throughout most  of  science,  including
pharmacometrics.   A single realization of  a random variable is implicitly treated as if  it  had large sample
asymptotic generality suitable for making trustworthy decisions regarding models.  Unfortunately this is just not
so [17, 36].  AIC has been shown to be asymptotically equivalent to leave-one-out cross-validation [37, 38], but
the present work illustrates the danger of relying on single realizations of asymptotically valid statistics.  In my
opinion such methods ought to be considered obsolete model selection approaches suitable for the time when
they were invented, before powerful computing became available.  Why rely on asymptotics when now we can
use  powerful  computing  to  do  better  [19]?   Relatively  little  has  been  written  regarding  the  variability  of
penalized likelihoods [39, 40], but this work illustrates the fact that they too are random variables and that
perturbing the data, as e.g. by taking bootstrap samples, will result in a distribution of such values.  Since the
penalty terms in AIC and BIC are intended as valid only in large sample approximations, using a distribution of
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AIC or BIC values probably offers no advantage over using the distribution of log-likelihood itself.  With BS-
CV one can directly compare the medians for log-likelihood for testing data for predictive accuracy.
Future work could involve the use of NONMEM and other error models (Monolix presently lacks the same
flexibility  for  error  models  that  NONMEM  has),  other  outcome  measures  (e.g.,  survival  curves,  logistic
regression),  improved  modeling  tools  which  could  make  it  easier  to  do  BS-CV,  and  comparisons  to  other
methods of cross-validation, including the extremes of 2-fold and LOOCV as noted above.  What are the pros
and cons of BS-CV compared to these extremes, especially as they relate to the bias vs. variance tradeoff?  Are
the results one gets sensitive to the algorithm used to calculate the conditional likelihood?  Does the ordering of
models change when changing algorithms?  There are variations on the basic bootstrap (e.g.,  stratification).
Since  BS-CV  is bootstrapping but  with  the  essential  distinction  of  keeping  track of  which  items  were  not
selected in a particular bootstrap iteration so as to have a testing data set, each of the bootstrap variations could
also be adapted for BS-CV.  To adapt BS-CV for automation such as for genetic algorithms [41, 42] it may be
helpful to quantitate overfitting by the degree of positive versus negative ε-shrinkage, by the ratio of the medians
for  –2LL for training versus testing data, or by some other statistic and use this as a constraint in the genetic
algorithm.
Conclusions
The purpose of this work was to explain some shortcomings of current practice, to introduce a better way,
and to demonstrate it with real data.  The main goals were two-fold: to demonstrate the utility of bootstrap cross-
validation as a practical tool for pharmacometric model selection and to evaluate various summary statistics as to
which of them would be the most useful in regards to BS-CV model selection.  A further pharmacodynamics
goal  was to see if  one could use only subtle statistical  differences to distinguish between different  indirect
response models that otherwise had very similar time course profiles (as may be useful if one were ignorant of
the mechanism of action of some drug).  BS-CV was applied to 13 PK models and 12 PD models using the
warfarin data set often used for teaching purposes in population PK-PD and included in Monolix.  BS-CV was
shown to provide an objective, nonparametric basis for PK-PD model selection based on predictive ability.  The
most  persuasive  summary statistic  is  the  –log(1  –  r2)  metric  for  the  line  of  observations  versus  individual
predictions, also denoted SMPQ.  This a simple, direct measure of goodness of fit that increases to infinity as
residuals go to 0.  For testing data, it is a direct measure of predictive accuracy.
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Model Observation model Individual model
1 y1 = Cc + (a1 + b1×Cc) × e   log(ka) = log(ka_pop) + eta_ka
basic 1-cmt model
  log(V)  = log(V_pop) + eta_V
  log(Cl) = log(Cl_pop) + eta_Cl
2 y1 = Cc + (a1 + b1×Cc) × e   log(Tlag) = log(Tlag_pop) + eta_Tlag
added Tlag
  log(ka) = log(ka_pop) + eta_ka
  log(V)  = log(V_pop) + eta_V
  log(Cl) = log(Cl_pop) + eta_Cl
3 y1 = Cc + (a1 + b1×Cc) × e   log(Tlag) = log(Tlag_pop) + eta_Tlag
added V(LnWt70)
  log(ka) = log(ka_pop) + eta_ka
  log(V)  = log(V_pop) + beta_V_LnWt70×LnWt70 + eta_V
  log(Cl) = log(Cl_pop) + eta_Cl
4 y1 = Cc + (a1 + b1×Cc) × e   log(Tlag) = log(Tlag_pop) + eta_Tlag
added Cl(LnWt70)
  log(ka) = log(ka_pop) + eta_ka
  log(V)  = log(V_pop) + beta_V_LnWt70×LnWt70 + eta_V
  log(Cl) = log(Cl_pop) + beta_Cl_LnWt70×LnWt70 + eta_Cl
5 y1 = Cc + (a1 + b1×Cc) × e   log(Tlag) = log(Tlag_pop) + eta_Tlag
added corr(Cl, V)
  log(ka) = log(ka_pop) + eta_ka
  log(V) = log(V_pop) + beta_V_LnWt70×LnWt70 + eta_V
  log(Cl) = log(Cl_pop) + beta_Cl_LnWt70×LnWt70 + eta_Cl
Correlations
  id : {Cl, V}
6 y1 = Cc + (a1 + b1×Cc) × e   log(Tlag) = log(Tlag_pop) + eta_Tlag
similar to 4, but 2-cmt
  log(ka) = log(ka_pop) + eta_ka
  log(Cl) = log(Cl_pop) + beta_Cl_LnWt70×LnWt70 + eta_Cl
  log(V1) = log(V1_pop) + beta_V1_LnWt70×LnWt70 + eta_V1
  log(Q)  = log(Q_pop) + eta_Q
  log(V2) = log(V2_pop) + beta_V2_LnWt70×LnWt70 + eta_V2
7 y1 = Cc + (a1 + b1×Cc^c1) × e   log(Tlag) = log(Tlag_pop) + eta_Tlag
changed error model (c1≠1)
  log(ka) = log(ka_pop) + eta_ka
  log(Cl) = log(Cl_pop) + beta_Cl_LnWt70×LnWt70 + eta_Cl
  log(V1) = log(V1_pop) + beta_V1_LnWt70×LnWt70 + eta_V1
  log(Q) = log(Q_pop) + eta_Q
  log(V2) = log(V2_pop) + beta_V2_LnWt70×LnWt70 + eta_V2
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Model Observation model Individual model
8 y1 = Cc + sqrt(a1^2 + 
(b1×Cc^c1)^2) × e
  log(Tlag) = log(Tlag_pop) + eta_Tlag
changed error model to (full)
combined2 (c1≠1)
  log(ka) = log(ka_pop) + eta_ka
  log(Cl) = log(Cl_pop) + beta_Cl_LnWt70×LnWt70 + eta_Cl
  log(V1) = log(V1_pop) + beta_V1_LnWt70×LnWt70 + eta_V1
  log(Q) = log(Q_pop) + eta_Q
  log(V2) = log(V2_pop) + beta_V2_LnWt70×LnWt70 + eta_V2
9 y1 = Cc + sqrt(a1^2 + 
(b1×Cc)^2) × e
  log(Tlag) = log(Tlag_pop) + eta_Tlag
simplified combined2 error model
  log(ka) = log(ka_pop) + eta_ka
  log(Cl) = log(Cl_pop) + beta_Cl_LnWt70×LnWt70 + eta_Cl
  log(V1) = log(V1_pop) + beta_V1_LnWt70×LnWt70 + eta_V1
  log(Q) = log(Q_pop) + eta_Q
  log(V2) = log(V2_pop) + beta_V2_LnWt70×LnWt70 + eta_V2
10 y1 = Cc + (a1 + b1×Cc) × e   log(Tlag) = log(Tlag_pop) + eta_Tlag
Cl(LnAge31, LnWt70), combined1
error model
  log(ka) = log(ka_pop) + eta_ka
  log(Cl) = log(Cl_pop)+ beta_Cl_LnAge31×LnAge31 + 
beta_Cl_LnWt70×LnWt70 + eta_Cl
  log(V1) = log(V1_pop) + beta_V1_LnWt70×LnWt70 + eta_V1
  log(Q) = log(Q_pop) + eta_Q
  log(V2) = log(V2_pop) + beta_V2_LnWt70×LnWt70 + eta_V2
11 y1 = Cc + sqrt(a1^2 + 
(b1×Cc)^2) × e
  log(Tlag) = log(Tlag_pop) + eta_Tlag
Cl(LnAge31, LnWt70)
combined2 error model
  log(ka) = log(ka_pop) + eta_ka
  log(Cl) = log(Cl_pop) + beta_Cl_LnAge31×LnAge31 + 
beta_Cl_LnWt70×LnWt70 + eta_Cl
  log(V1) = log(V1_pop) + beta_V1_LnWt70×LnWt70 + eta_V1
  log(Q) = log(Q_pop) + beta_Q_LnAge31×LnAge31 + eta_Q
  log(V2) = log(V2_pop) + beta_V2_LnWt70×LnWt70 + eta_V2
12 y1 = Cc + (a1 + b1×Cc) × e   log(Tlag) = log(Tlag_pop) + eta_Tlag
  log(ka) = log(ka_pop) + eta_ka
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Model Observation model Individual model
Cl(LnAge31),
combined1 error model
  log(Cl) = log(Cl_pop) + beta_Cl_LnAge31×LnAge31 + eta_Cl
  log(V1) = log(V1_pop) + beta_V1_LnWt70×LnWt70 + eta_V1
  log(Q) = log(Q_pop) + eta_Q
  log(V2) = log(V2_pop) + beta_V2_LnWt70×LnWt70 + eta_V2
13 y1 = Cc + sqrt(a1^2 + 
(b1×Cc)^2) × e
  log(Tlag) = log(Tlag_pop) + eta_Tlag
Cl(LnAge31),
combined2 error model
  log(ka) = log(ka_pop) + eta_ka
  log(Cl) = log(Cl_pop) + beta_Cl_LnAge31×LnAge31 + eta_Cl
  log(V1) = log(V1_pop) + beta_V1_LnWt70×LnWt70 + eta_V1
  log(Q) = log(Q_pop) + eta_Q
  log(V2) = log(V2_pop) + beta_V2_LnWt70×LnWt70 + eta_V2
Table 1.  Pharmacokinetic error (observation) and individual models for the 1 and 2 compartment structural models 1-6 and
7-13 respectively.  The combined1 and combined2 error models are Monolix’ terminology.  Covariates were scaled so that
LnWt70 refers to log(weight/70) where log is the natural logarithm, 70 is the mean weight (in kg) of the subjects, and
likewise LnAge31 for scaled age.
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Model Median SMPQ
1 4.959724
2 4.950134
3 4.932914
4 4.896363
5 4.925444
6 4.943017
7 4.905763
8 4.925442
9 4.927192
10 4.881644
11 4.934955
12 4.910872
Table 2.  The predictive ability of the IRM PD models evaluated is all about the same.
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Figure 1.  –2LL for original, training, and testing data.
21
Figure 2.  AIC for original, training, and testing data.
22
Figure 3.  BIC for original, training, and testing data.
23
Figure 4.  RSS for original, training, and testing data.
24
Figure 5.  RMSE for original, training, and testing data.
25
Figure 6.  SAD for original, training, and testing data.
26
Figure 7.  MAD for original, training, and testing data.
27
Figure 8.  SMPQ for original, training, and testing data.
28
Figure 9.  ε-Shrinkage (via EBE) for original, training, and testing data.
29
Figure 10.  ε-Shrinkage (via simulations) for original, training, and testing data.
30
Figure 11.  –2LL for original, training, and testing data.
31
Figure 12.  AIC for original, training, and testing data.
32
Figure 13.  BIC for original, training, and testing data.
33
Figure 14.  RSS for original, training, and testing data.
34
Figure 15.  RMSE for original, training, and testing data.
35
Figure 16.  SAD for original, training, and testing data.
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Figure 17.  MAD for original, training, and testing data.
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Figure 18.  SMPQ for original, training, and testing data.
38
Figure 19.  ε-Shrinkage (via EBE) for original, training, and testing data.
39
Figure 20.  ε-Shrinkage (via simulations) for original, training, and testing data.
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